Key Highlights

  • BNTC reported a fiscal Q1 2027 net loss of US$12,925 thousand, or US$0.26 per share.
  • Research and development expenses were US$8,618 thousand versus US$3,370 thousand.
  • General and administrative expenses were US$5,859 thousand versus US$6,433 thousand.
  • Cash and cash equivalents were US$176 million at September 30, 2026, with no outstanding borrowings.

BNTC filed its Quarterly Report on November 13, 2026, for the fiscal first quarter of 2027, ended September 30. Research and Development expenses were US$8,618 thousand, versus US$3,370 thousand. The company said the expenses relate primarily to clinical development of BB-301 for oculopharyngeal muscular dystrophy, and that the increase was due to higher contract Manufacturing activity, activities related to natural history and dosing studies, and a US$1.1 million increase in stock-based compensation.

General and administrative expenses were US$5,859 thousand, versus US$6,433 thousand. The company tied the decrease primarily to a US$0.7 million decrease in stock-based compensation. Total operating expenses were US$14,477 thousand versus US$9,803 thousand, and the loss from operations equaled those amounts.

Other Income, Net Loss and Cash Flow

Interest income, net, was US$1,576 thousand versus US$1,011 thousand. The foreign currency transaction loss was US$(23) thousand versus US$(89) thousand, and other expense, net, was US$(1) thousand versus US$(84) thousand. Total other income, net, was US$1,552 thousand versus US$838 thousand.

Net loss was US$(12,925) thousand, versus US$(8,965) thousand, and net loss per share was US$(0.26) versus US$(0.22). Weighted average shares were 49,487,369 versus 41,521,280. Net cash used in Operating Activities was US$3,623 thousand versus US$3,351 thousand, with no investing or financing cash flows in either period.

Liquidity, Warrants and BB-301 Development

The company reported cash and cash equivalents of US$176 million at September 30, held in bank accounts, and accumulated losses of US$287 million. It said it had no outstanding borrowings or Credit facilities. Under a sales agreement entered on October 11, 2024, it may sell shares of common stock with an aggregate offering price of up to US$75.0 million in at-the-market offerings. It also had 19,551,609 warrants outstanding to purchase common stock, versus 20,017,501 at June 30, 2026.

BB-301 is an AAV9-based gene therapy using the company's DNA-directed RNA interference silence-and-replace platform. The company said the FDA approved its investigational new drug application in June 2023, the first subject in the Phase 1b/2a trial was treated in November 2023, all Cohort 1 subjects have completed 12-month follow-up, and three subjects have been treated in Cohort 2. BB-301 has Orphan Drug Designation and Fast Track Designation from the FDA and Orphan Drug Designation in the European Union.

Quarter in Review: Trial Spending and Balance Sheet

BNTC's fiscal first quarter combined higher research and development spending and a net loss of US$12,925 thousand with cash of US$176 million and no borrowings. The company said it expects research and development expenses to increase with continued development of its OPMD program.